title: Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors.
abstract: BACKGROUND
  The goal of this study was to determine the prognostic factors associated with an improved overall outcome after stereotactic body radiotherapy (SBRT) for primary lung cancer and metastatic lung tumors.
  
  
  METHODS
  A total of 229 lung tumors in 201 patients were included in the study. SBRT of 45 Gy in 3 fractions, 48 Gy in 4 fractions, 60 Gy in 8 fractions or 60 Gy in 15 fractions was typically used to treat 172 primary lungs cancer in 164 patients and 57 metastatic lung tumors in 37 patients between January 2001 and December 2011. Prognostic factors for local control (LC) and overall survival (OS) were analyzed using a Cox proportional hazards model.
  
  
  RESULTS
  The median biologically effective dose was 105.6 Gy based on alpha/beta = 10 (BED10). The median follow-up period was 41.9 months. The 3-year LC and OS rates were 72.5% and 60.9%, and the 5-year LC and OS rates were 67.8% and 38.1%, respectively. Radiation pneumonitis of grades 2, 3 and 5 occurred in 22 patients, 6 patients and 1 patient, respectively. Multivariate analyses revealed that tumor origin (primary lung cancer or metastatic lung tumor, p < 0.001), tumor diameter (p = 0.005), BED10 (p = 0.029) and date of treatment (p = 0.011) were significant independent predictors for LC and that gender (p = 0.012), tumor origin (p = 0.001) and tumor diameter (p < 0.001) were significant independent predictors for OS.
  
  
  CONCLUSIONS
  SBRT resulted in good LC and tolerable treatment-related toxicities. Tumor origin and tumor diameter are significant independent predictors for both overall survival and local control.
authors: Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, Japan. t.yamamoto@rad.med.tohoku.ac.jp.
authors: Takaya
authors: T
authors: Yamamoto
authors: Keiichi
authors: K
authors: Jingu
authors: Yuko
authors: Y
authors: Shirata
authors: Masashi
authors: M
authors: Koto
authors: Haruo
authors: H
authors: Matsushita
authors: Toshiyuki
authors: T
authors: Sugawara
authors: Masaki
authors: M
authors: Kubozono
authors: Rei
authors: R
authors: Umezawa
authors: Keiko
authors: K
authors: Abe
authors: Noriyuki
authors: N
authors: Kadoya
authors: Youjirou
authors: Y
authors: Ishikawa
authors: Maiko
authors: M
authors: Kozumi
authors: Noriyoshi
authors: N
authors: Takahashi
authors: Ken
authors: K
authors: Takeda
authors: Yoshihiro
authors: Y
authors: Takai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D016634:Radiosurgery / Q000009:adverse effects; D016896:Treatment Outcome